Company News For Mar 5, 2019

Zacks Equity Research Published on March 05, 2019

The Children's Place, Inc.’s (PLCE - Free Report) shares tanked 10.3% after the company reported fourth quarter 2018 earnings per share of $1.10, lower than the Zacks Consensus Estimate of $2.11 a share
Biogen Inc.’s (BIIB - Free Report) shares declined 2.1% after the company announced that it had agreed to purchase Nightstar Therapeutics plc for $25.50 a share
Shares of Ascendis Pharma A/S (ASND - Free Report) rallied 74% after the company announced that its TransCon Growth Hormone trial had achieved the desired primary end result
Shares of Takeda Pharmaceutical Company Limited (TAK - Free Report) , rose 5.2% after the company announced that it had entered into a partnership with Lupus Therapeutic Partners to start Phase 1 trial for lupus treatment

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.